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Feline Chronic Gingivostomatitis Syndrome (FCGS) is a common disease in clinical practice. Among the therapeutic
options available, long-acting corticosteroids are frequently used due to their anti-inflammatory and
immunosuppressive properties. Although they may improve the clinical symptoms, they can lead to a progressive
form of the disease that becomes refractory to treatment. Furthermore, their direct relationship with type II diabetes
mellitus (DM) is well known. Consequently, these drugs are controversial and not recommended for routine
management of FCGS. Recombinant feline interferon-omega (rFeIFN-ω) is an immunomodulatory compound.
Recently, its daily oral administration has been shown to be successful in treating refractory cases of FCGS. This case
study describes two clinical cases of type II DM complicated by FCGS. Both animals were calicivirus positive and
they had been previously treated with long-acting corticosteroids, which may have been the major cause of DM.
The two cats were treated with glargine insulin (Lantus, starting dose 1 IU/cat twice daily (BID)), achieving remission
10 and 18 weeks later respectively. Considering the difficulty with control of FCGS in these animals, an oral daily
dose of rFeIFN-ω was started as an alternative to long-acting corticosteroids. In both cats oral clinical signs
gradually improved and 60 days after the start of therapy the owners reported a significant relief of pain during
mastication. According to the authors’ knowledge, this is the first case report that describes the successful use of
rFeIFN-ω in the management of FCGS in type II diabetic cats, in which long-acting corticosteroids are
contraindicated.
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Feline chronic gingivostomatitis syndrome (FCGS) is a
multifactorial disease, very commonly seen in clinical
practice [1]. It is described as a severe oral inflammation
(gingivitis, stomatitis and/or periodontitis) and may be
secondary to various causes such as neoplasia, toxins or
even metabolic disease [2]. In some cases, a cause is not
found but regarding the chronic inflammation observed
in histopathology samples, an immune mediated etiology
should always be considered [3]. Infectious viral diseases* Correspondence: rleal@fmv.utl.pt
1Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA),
Faculdade de Medicina Veterinária, Technical University of Lisbon (TULisbon),
Av. Universidade Técnica, 1300-477 Lisbon, Portugal
Full list of author information is available at the end of the article
© 2013 Leal et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orare also an important trigger of FCGS [1,4]. Feline
immunodeficiency virus (FIV) and feline leukemia virus
(FeLV) may lead to FCGS due to an induced immune
suppression and dysregulation [5,6]. Additionally feline
herpesvirus (FHV-1) and feline calicivirus (FCV) have
been well-described as potential factors in the develop-
ment of FCGS [7]. In fact, a previous study showed that
88% of cats with chronic gingivostomatitis were excreting
FHV-1 and FCV [8]. Animals with FCGS usually present
with a poor body condition, dysphagia and mild to moder-
ate anorexia [2]. Most therapeutic approaches are not very
effective and relapses are frequent [2]. Among the avail-
able therapeutic options, dental extraction, antibiotics
and corticosteroids or non-steroidal anti-inflammatory
drugs (NSAIDs) are usually recommended [2,9]. Due to. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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long-acting corticosteroids are more frequently used in
first-opinion clinical practice [2,3,9]. They are historic-
ally described as a good therapeutic approach to FCGS
due to the fact that they reduce oral inflammation and
control immune-mediated causes, leading to a rapid
improvement, an increased appetite and a relief of oral
pain [2,3,9]. In spite of their short-term efficacy at control-
ling the symptoms of the syndrome, long-acting cortico-
steroids are also a well-known cause of insulin-resistance
[10,11], by inducing chronic hyperglycemia which can
lead to a glucotoxic beta-cell insufficiency [10]. Therefore,
being a potential cause of type II diabetes mellitus (DM)
in cats, long-acting corticosteroid use is controversial in
this species in general.
In refractory cases of FCGS, where dental extraction
and antibiotics are not sufficient to induce remission of
the lesions, there are few therapeutic alternatives to cor-
ticosteroids [12]. Recombinant feline interferon-omega
(rFeIFN-ω; Virbagen, Virbac) is an immune-modulator
drug currently licensed in Europe for treatment of feline
retroviral infections [13-15]. According to the manufac-
turer’s instructions, the licensed protocol consists of three
cycles of five daily administrations of 1 MU/kg subcutane-
ously (SC) at days 0, 14 and 60. However other dosages
and routes have also been used in the management of
other diseases. For instance, alternative subcutaneous and
topical protocols were tried in feline coronavirus and
FHV-1 infection, respectively [16,17]. Also in cases of
FCGS (some of them FCV positive), a study suggested the
benefit of intra-lesional administration of rFeIFN-ω [18].
More recently, its oral administration was documented in
noneffusive feline infectious peritonitis [19] and in refrac-
tory FCGS, particularly in an efficacy study which com-
pared the use of an oral rFeIFN-ω protocol with the use of
oral corticosteroids [12]. This study concluded that oral
rFeIFN-ω was associated with a significant clinical im-
provement of FCGS lesions [12]. Furthermore, there was
no difference between this protocol and corticosteroids
except on pain control, where animals treated with
rFeIFN-ω achieved a better pain relief [12]. Therefore, as
oral rFeIFN-ω is a useful alternative management option
for refractory FCGS, it may also be of particular interest
in cats where corticosteroid administration is contrain-
dicated, such as those with DM. This report underlines
the relevance of rFeIFN-ω by describing two clinical cases
of diabetic cats in which it was successfully administered
as an alternative therapy for concurrent FCGS.
Case presentation
Case one
A 15 year-old castrated domestic short-hair (DSH) cat was
presented to the endocrinology service of the Veterinary
Teaching Hospital – Faculty of Veterinary Medicine,Techinical University of Lisbon (FMV-UTL) for polyuria/
polydipsia (Pu/Pd), mild anorexia and weight loss. Prior
to this consultation, the animal had been managed by
the referring vet for severe dysphagia and weight loss,
secondary to FCGS, diagnosed one year before. Consid-
ering the positive calicivirus status (assessed by poly-
merase chain reaction (PCR) analysis of an oral swab),
an infectious origin had been assumed. A partial ex-
odontia had been performed without significant im-
provement. Furthermore, the cat had been recurrently
treated with antibiotics (cefovecin; 8 mg/kg SC every
two weeks) and periodically with long-acting corticoste-
roids (methylprednisolone acetate; 10 mg intramuscu-
larly every four to six weeks). On clinical examination,
the cat presented with a moderate gingivitis and caudal
stomatitis which extended to the palatoglossal folds.
After the initial workup (hematology, biochemistry,
urine analysis and abdominal ultrasound), a type II DM
complicated with ketoacidosis was diagnosed. After ini-
tial stabilization with intravenous fluids and a regular
insulin protocol, the cat was progressively fed with a
diabetic specific diet (Purina DM) and insulin-glargine
(1 IU/cat SC BID) was started. After three days of
hospitalization and a good initial response to this insu-
lin, the cat was discharged. The owners performed
weekly home blood glucose curves (HBGC) and the in-
sulin dose was adjusted according to the glycemia re-
sults. Ten weeks later, after a gradual decrease of insulin
therapy, the cat went into remission of the DM and in-
sulin therapy was stopped. However, after the remission
of the diabetic clinical signs such as polyphagia, the gin-
givitis and caudal stomatitis got worse. Despite the good
control of the DM and therapeutic trials with antibiotics
(cefovecin; 8 mg/kg SC every two weeks), gastric pro-
tectants (sucralfate; 0.5 g/cat per-os (PO) BID) and
NSAID (meloxicam; 0.1 mg/kg PO, SID), the FCGS
progressed, with the cat developing a severe dysphagia
with hypersalivation and weight loss. Due to the previ-
ous history of type II DM associated with long-acting
corticosteroid therapy, an oral rFeIFN-ω protocol
(0.1 MU PO SID) was started, with the owner’s informed
consent. During the first two weeks of treatment, oral
disinfectants (antiseptic oral solution: Collu-Hextril,
Johnson & Johnson Lda; 1 diluted portion PO SID and
enzymatic gel: Orozyme, Ceva; 1 cm ointment PO SID)
and an antibiotic (cefovecin; 8 mg/kg SC administered
once) were concurrently prescribed. After this initial
therapeutic approach, only rFeIFN-ω was administered.
The cat started to improve gradually, and 2 months
later the owners described a significant improvement of
mastication and reduced evidence of pain. The treat-
ment was continued and animal was evaluated monthly.
Six months later, at the date of the last evaluation, the
cat had only a mild gingivitis and stomatitis, without
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rFeIFN-ω, which was not discontinued due to the good
clinical results obtained.
Case two
A 14 year-old castrated DSH cat was presented to the
endocrinology service of the Veterinary Teaching Hospital
FMV-UTL for DM monitoring. The animal had been di-
agnosed with DM four weeks prior to the consultation,
following an acute onset of Pu/Pd and polyphagia. Apart
from DM, it had been recurrently seen by the referring
veterinarian due to FCGS with concurrent documented
calicivirus infection, diagnosed two years previously, based
on a PCR analysis of an oral swab. The cat had been inter-
mittently treated with antibiotics (potentiated amoxicillin
15-20 mg/kg PO BID) and corticosteroids (prednisolone
0.5-1 mg/kg PO SID intermittently for three-five days)
until six weeks before the development of DM. The cat
was first started on veterinary lente-insulin (0.5 IU/kg
BID) and fed with an appropriate diet for DM (Purina
DM). At clinical presentation, the animal had a significant
alveolar and caudal mucositis, with concurrent inflamma-
tion of palatoglossal folds and severe pain on mouth ma-
nipulation. No other abnormalities were observed. The
owners had made some HBGC that revealed inconstant
values. Considering the difficult control of glycaemia and
the apparent weak response to lente-insulin, the insulin
was changed to insulin-glargine (1 IU/cat SC BID). After
three days of hospitalization, the animal was discharged
and owners performed weekly HMBG curves. According
to these measures, the insulin-glargine dose was adjusted
weekly. After five weeks, the FCGS progressed with devel-
opment of a severe dysphagia and hypersalivation. With
the owner’s informed consent, animal was started on the
oral rFeIFN-ω protocol. The use of concurrent oral disin-
fectants was advised but was not regularly performed by
the owner. Gradually, the FCGS started to improve and
the insulin-glargine requirement decreased. Eighteen
weeks after starting insulin therapy, the animal achieved
clinical remission of the DM with no further requirement
for insulin therapy. The oral rFeIFN-ω was continued and
the animal was evaluated monthly. Despite the persistence
of gingivitis and caudal stomatitis, the owners reported a
significant pain relief, more evident 60 days after the onset
of therapy. The treatment was continued. Three months
later, five months after the beginning of therapy, the cat
presented with a good clinical condition with less pain on
opening the mouth and a concurrent clinical improve-
ment of the FCGS with less extensive lesions, a reduced
hypersalivation and a more comfortable mastication.
Conclusions
This report describes two cases of clinical remission of
DM in cats with FCGS under insulin-glargine and dietarymanagement. Both cases had been previously treated
with corticosteroids, which are considered a risk-factor
for DM in cats [10]. Although the corticosteroids were
discontinued, these animals required insulin therapy
and a concurrent suitable diet to control the DM. While
one cat started insulin therapy with insulin-glargine, the
other began the treatment with lente-insulin and was
later switched to insulin-glargine. Clinical remission
was obtained 10 and 18 weeks after starting insulin
therapy, respectively. This is in agreement with previous
studies that describe a high-rate of clinical remission in
feline DM managed with insulin-glargine and suitable
diets [20-22].
Concurrently, these animals were presenting with FCGS,
and both cases were infected with calicivirus. This disease
could have lead to a more difficult management of DM. In
the first case the animal went into clinical DM remission
and few days later the FCGS symptoms worsened. In the
second one, the FCGS was a clinical problem during insu-
lin therapy. Despite being associated with a previous good
clinical improvement and a reduction of lesions, cortico-
steroids were contraindicated in both cases. Therefore,
based on previous clinical trials [12], an oral protocol of
rFeIFN-ω was successfully applied. In both cases, clinical
improvement was gradually observed and was significantly
marked (and noted by owners, who remarked that the ani-
mals started eating without discomfort and had reduced
hypersalivation) around 60 days after the onset of therapy.
This was particularly evident in the second case where
rFeIFN-ω therapy was associated with a clinical improve-
ment of oral lesions and a concurrent reduced insulin dose
requirement which culminated in type II DM remission.
This is in agreement with the previously cited work that
describes an overall relief of pain in refractory cases of
FCGS [12]. It is also in agreement with multiple anecdotal
reports that describe a rapid improvement in well-being in
cats with FCGS during oral rFeIFN-ω treatment, but with
a period of three to six months being necessary in some
severe cases before the lesions are fully resolved, especially
where there has been regular previous use of corticoste-
roids (D. McGahie – personal communication). Although
there are no studies that clearly detail the immunomodu-
latory mechanisms of oral rFeIFN-ω use, it has been
proven that oral human interferon-alpha administration
may potentiate a local T-helper 1 response (Th1) [23]. In
fact, human interferon-alpha seems to increase the expres-
sion of gamma-interferon, a Th1 cytokine inducer, while
it reduces the Interleukin-4 production, responsible for
a T-helper 2 response [23]. Recognizing that the Th1 re-
sponse is an important immunological pathway against
viral infections [23], it seems reasonable that rFeIFN-ω
and human interferon-alpha (both type I interferons)
may have a similar local action. Therefore, this Th1-
enhancement may explain the clinical improvement
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therapy. Further controlled prospective studies are needed
to reinforce these clinical findings, correlating them
with the local immune response. These two clinical
cases describe the successful use of oral rFeIFN-ω in
diabetic cats with FCGS as an appropriate alternative to
corticosteroid treatment where its administration is
contraindicated.
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